<DOC>
	<DOCNO>NCT01259492</DOCNO>
	<brief_summary>This study evaluate efficacy safety methylphenidate hydrochloride extend release compare placebo adult patient childhood-onset attention deficit/hyperactivity disorder ( ADHD ) .</brief_summary>
	<brief_title>Efficacy Safety Study Methylphenidate Hydrochloride Extended Release Adults With Childhood-onset Attention Deficit/Hyperactivity Disorder ( ADHD )</brief_title>
	<detailed_description />
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<mesh_term>Methylphenidate</mesh_term>
	<criteria>Inclusion criterion : 1 . Diagnosis attention deficit/hyperactivity disorder ( ADHD ) start childhood 2 . Female patient childbearing potential must practice acceptable method contraception . Exclusion criterion : 1 . Patients body mass index ( BMI ) less 18.5 kg/m2 35 kg/m2 2 . History alcohol substance abuse within last six month . 3 . History seizure use anticonvulsant medication . 4 . Any psychiatric condition require medication may interfere study participation . 5 . Preexisting cardiovascular disorder include severe hypertension , heart failure , myocardial infraction , etc . 6 . Significant respiratory , hepatic , gastrointestinal , renal , hematological oncologic disorder 7 . Diagnosis glaucoma , hyperthyroidism , pheochromocytoma 8 . Diagnosis family history Tourette 's syndrome 9 . Preexisting cerebrovascular disorder cerebral aneurysm , vascular abnormality include vasculitis stroke Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Attention Deficit /Hyperactivity Disorder , hyperactivity</keyword>
</DOC>